Decoding TROP2 in breast cancer: significance, clinical implications, and therapeutic advancements
Frontiers in Oncology · 24.10.2023 · 13
DOI: 10.3389/fonc.2023.1292211 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 24.10.2023. Verfasst von Liqin Yao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgical Oncology, The First Affiliated Hospital, Huzhou University School of Medicine, Huzhou, Zhejiang, China. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Breast cancer is a heterogeneous disease characterized by distinct molecular subtypes, varied prognoses, and differential treatment responses. Understanding the molecular landscape and identifying therapeutic targets, such as trophoblast cell-surface antigen 2 (TROP2), is vital. TROP2 is notably overexpressed in breast cancer, playing a significant role in tumor growth, invasion, metastasis, and treatment resistance. While significant progress has been made in targeting TROP2 in breast cancer, several challenges and knowledge gaps remain. These challenges include the heterogeneity of TROP2 expression within breast cancer subtypes, resistance to its targeted therapies, potential off-target effects, limited therapeutic agents, and identifying optimal combination treatments. Integrating findings from clinical trials into clinical practice further complicates the landscape. This review article delves deep into TROP2 in breast cancer, highlighting its expression patterns, clinical implications, and therapeutic advancements. By understanding the role of TROP2, we can pave the way for personalized treatments, and transform the landscape of breast cancer care.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Breast Surgical Oncology, The First Affiliated Hospital, Huzhou University School of Medicine, Huzhou, Zhejiang, China.
- Department of Pathology and Clinical Laboratories, Tongxu County Hospital of Traditional Chinese Medicine, Kaifeng, Henan, China.
- Department of Medicine, Moores Cancer Center, and Sanford Stem Cell Institute, University of California San Diego, La Jolla, CA, United States.
Zitieren
APA
Yao, L., Chen, J., & Ma, W. (2023). Decoding TROP2 in breast cancer: significance, clinical implications, and therapeutic advancements. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1292211
Vancouver
Yao L, Chen J, Ma W. Decoding TROP2 in breast cancer: significance, clinical implications, and therapeutic advancements. Frontiers in Oncology. 2023;13. doi:10.3389/fonc.2023.1292211
BibTeX
@article{Yao2023,
author = {Yao, Liqin and Chen, Junfeng and Ma, Wenxue},
title = {Decoding TROP2 in breast cancer: significance, clinical implications, and therapeutic advancements},
journal = {Frontiers in Oncology},
year = {2023},
volume = {13},
doi = {10.3389/fonc.2023.1292211}
}
EUVIMED